ALK G1202R
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene ALK
Variant G1202R
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions ALK G1202R lies within the protein kinase domain of the Alk protein (UniProt.org). G1202R confers a gain of function to the Alk protein as indicated by increased colony formation, decreased Cdh1 expression, increased migration and invasion, and increased expression of metastatic factors Cdh2, Vim, Mmp2, Mmp9, and Slug in the context of EML4-ALK compared to expression of EML4-ALK alone in cell culture (PMID: 35085771), and has been demonstrated to confer resistance to Alk inhibitors in the context of ALK fusions (PMID: 22277784, PMID: 24736079, PMID: 35085771).
Associated Drug Resistance Y
Category Variants Paths

ALK mutant ALK act mut ALK G1202R

ALK mutant ALK G1202X ALK G1202R

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_004304.5
gDNA chr2:g.29220747C>T
cDNA c.3604G>A
Protein p.G1202R
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_004304 chr2:g.29220747C>T c.3604G>A p.G1202R RefSeq GRCh38/hg38
NM_004304.4 chr2:g.29220747C>T c.3604G>A p.G1202R RefSeq GRCh38/hg38
NM_004304.5 chr2:g.29220747C>T c.3604G>A p.G1202R RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05170204 Phase III Durvalumab Alectinib A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (HORIZON 1) Active, not recruiting USA | SWE | POL | ITA | GBR | FRA | DEU | BRA | BEL | AUS 9
NCT04644315 Phase II Alectinib A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T) Terminated USA 0
NCT03737994 Phase II Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Terminated USA 0